5 Red Flags on MannKind's Balance Sheet

Image source Getty Images Since the day MannKind s NASDAQ MNKD inhaled insulin device Afrezza earned FDA approval just over two years ago the company s stock has lost about 92 6 of its value 160 Now that MannKind s former marketing partner Sanofi 160 has